Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Boehringer Ingelheim
Colorcon
McKinsey
AstraZeneca

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Litigation Details for Pfizer Inc. v. Ranbaxy Laboratories Limited (D. Del. 2007)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Small Molecule Drugs cited in Pfizer Inc. v. Ranbaxy Laboratories Limited
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Pfizer Inc. v. Ranbaxy Laboratories Limited (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-05-03 15 Opening Brief in Support sought to put Teva 5,246,937 (“ 937 patent”); 5,840,763 (“ 763 patent”); to the hard choice of either… 5,246,937, 5,840,763, 5,866,581, 5,916,893, 118AII(L) Patents …5,866,581 (“ 581 patent”); 5,916,893 (“ 893 patent”); massive liability for patent infringement when… the and 6,124,304 (“ 304 patent”). The 937 patent is 937 patent expires or Teva prevails in…judgment that the patent [listed in the Famvir® Orange Book patents or that the patents Orange External link to document
2007-06-14 21 Reply Brief at least three patents-the 340 patent, the 5,229,137 patent, and the 5,989,588 patent. (DX BE.) This …114 patent to the Examiner. (DX D; DX L, Paper No. 14 at 118.) The 114 patent, like the 072 patent, reveals…has conclusively determined that the ‘893 patent (and its patent term extension) is not invalid or unenforceable…Defense To The ’893 Patent Ranbaxy did not make an obviousness challenge to the ‘893 patent at trial in the…accuse Perrigo of infringing U.S. Patent No. 5,817,340 (the “ 340 patent”) by filing Abbreviated New Drug External link to document
2007-06-14 22 Reply Brief 5,358,941; 5,681,590; 5,849,726; 6,008,207; 6,090,410; 6,194,004; 5,994,329; 6,015,801; and 6,225,294.…obtained U.S. Patent No. 4,924,011 (issued May 8, 1990) (“ '011 patent”) and U.S. Patent Re. No. 34,… the patent office in connection with the ‘Oll patent application and the '277 reissue patent application…required patent information relating to such patent has not been filed; (ii) that such patent has expired…may be sued for patent infringement lf the NDA sponsor or patent owner files a patent infringement suit External link to document
2008-06-18 64 Stipulation including without limitation U.S. patent 6,455,574 (“Caduet Patent”); WHEREAS, defendant/counterclaim…Warner-Lambert Export Limited (“Pfizer”) own U.S. patents covering the manufacture, sale and use of products…litigation relating to the Ranbaxy ANDA and Caduet Patents, and Ranbaxy desires to sell a generic product …claims of infringement by Pfizer under the Caduet Patent; WHEREAS, Pfizer and Ranbaxy have entered…granted Ranbaxy certain rights to its portfolio of patents relating to atorvastatin; NOW THEREFORE External link to document
2008-06-20 65 SO ORDERED including without limitation U.S. patent 6,455,574 (“Caduet Patent”); WHEREAS, defendant/counterclaim…Warner-Lambert Export Limited (“Pfizer”) own U.S. patents covering the manufacture, sale and use of products…litigation relating to the Ranbaxy ANDA and Caduet Patents, and Ranbaxy desires to sell a generic product …claims of infringement by Pfizer under the Caduet Patent; WHEREAS, Pfizer andR anbaxy have entered intoa…granted Ranbaxy certain rights to its portfolio of patents relating to atorvastatin; NOW THEREFORE, Pfizer External link to document
2008-06-24 66 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,455,574; (Attachments: # (1… including without limitation U.S. patent 6,455,574 (“Caduet Patent”); WHEREAS, defendant/counterclaim…; HOLDER OF PATENT OR TRADEMARK l 4,681,893 7/2 |/1987 Warner-Lambert Company 2 6,455,574 Bl 9/24/2002…and Stipulated lnjunclion (i'e Pulent NO. 6,455,574) CLERK PETER T. DALLEO, CLERK OF COURT …Pleading DATE OF PATENT OR TRADEMARK PATENT OR TRADEMARK NO. HOLDER OF PATENT OR TRADEMARK External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
Mallinckrodt
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.